Congratulate! Xinda biology / Lilly innovation PD-1 inhibitor Dabusu (xindilimab injection) is listed in the new national medical insurance catalog!

November 28, 2019 news / BIOON / -- innovent biologics is a biopharmaceutical company dedicated to R & D, production and sales of innovative drugs for the treatment of major diseases such as tumor, autoimmune and metabolic diseases Today, the company and Lilly pharmaceutical jointly announced that the innovative PD-1 inhibitor Dabusu (cindilimab injection) jointly developed by the two sides has been included in the category B scope of the new version of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue (2019 version) According to the official announcement, Dabusu ® (cindilimab injection) is the only PD-1 monoclonal antibody successfully listed in the national medical insurance catalog through medical insurance negotiation (details of medical insurance reimbursement and other relevant information shall be subject to the information publicized by the government.) Dabushu ® (recombinant all human anti-PD-1 monoclonal antibody, international trademark: tyvyt ®, common chemical name: sindilimab injection) is Xinda biology and Lilly The innovative PD-1 inhibitor jointly developed was officially approved by the State Drug Administration on December 24, 2018 for the treatment of relapsed or refractory classic Hodgkin's lymphoma after at least second-line systemic chemotherapy Dabusu ® (cindilimab injection) has entered the medical insurance system to prove that it meets the standards of the National Medical Insurance Bureau in terms of the clinical value of drugs, patient benefits, innovation, etc Sindilimab can enter the new national medical insurance catalogue, which will further improve the accessibility of patients to new high-quality immunotherapy drugs Dr Yu Dechao, founder, chairman and President of XinDa biopharmaceutical group, said: "in recent years, the country's effective reform has promoted the strategy of" healthy China "and constantly strive for the well-being of the people Thank you very much for the opportunity and recognition given to us by the government department, which makes cindilimab injection the only PD-1 McAb drug to enter the new national medical insurance catalogue Xinda biology adheres to the enterprise mission of "developing high-quality bio medicine affordable to the common people", will continue to support the country to deepen the reform of medical security, work together to improve the affordability and accessibility of drugs, and contribute to continuously meeting the growing needs of the people for a better life " Ji Liwen, President and general manager of Lilly China, said: "dabushu ® (cindilimab injection) is the first fruits of Lilly Cinda's strategic cooperation, and its listing in the first half of this year has brought many patients with innovative new options for immunotherapy of tumor The negotiation to enter the national medical insurance catalogue is to improve the accessibility of drugs and further reduce the economic burden of patients In the future, we will continue to deepen cooperation with Cinda and work with all parties to benefit Chinese patients through innovative drugs, medical services, payment methods and other dimensions " Liu Min, chief business officer of Xinda biopharmaceutical group and general manager of Xinda biopharmaceutical Shanghai Branch, said: "we believe that after dabushu (cindilimab injection) is included in the national medical insurance catalog, it will further reduce the economic burden of cancer patients and help more patients to obtain long-term and standardized drug treatment We will continue to actively respond to the relevant work of government departments at all levels, coordinate with the implementation of the medical insurance policy in various overall planning areas, and accelerate the access to the hospital We will continue to explore innovative payment methods with various parties, and strive to make more patients enjoy the health outcomes of scientific progress " Dabusu ® (cindilimab injection) is an innovative bio drug with international quality jointly developed by Cinda bio pharmaceutical and Lilly pharmaceutical in China Its listing application has been officially approved by the State Drug Administration The first indication approved is relapsed / refractory classic Hodgkin's lymphoma, and it was selected into the 2019 CSCO lymphoma diagnosis and treatment guidelines In November 2019, sindilimab injection became the only PD-1 inhibitor to enter the new national medical insurance catalogue Dabushu ® (sindilimab injection) is a monoclonal antibody against human immunoglobulin G4 (IgG4), which can specifically bind to the PD-1 molecule on the surface of T cells, thus blocking the PD-1 / programmed cell death-1 ligand-1, which leads to tumor immune tolerance, PD-L1) pathway can reactivate the antitumor activity of lymphocytes, so as to achieve the purpose of tumor treatment At present, more than 20 clinical studies (8 of which are registered clinical trials) are under way to explore the antitumor effect of sindilimab on other solid tumors At the same time, Cinda biology is carrying out clinical research of cindilimab injection in the United States Source: Xinda biology